205448-31-3Relevant articles and documents
Deuterated lucitanib compounds and use thereof
-
Paragraph 0054; 0055; 0057, (2019/12/25)
The invention discloses a compound represented by the formula (I) or optical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, wherein R-R are independently selected from H and D respectively, and are not H at the same time. The deuterated lucitanib compounds and the optical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereofprovided by the invention not only have the anticancer activity of lucitanib, but also have significant improvement in pharmacokinetics, have the metabolic stability obviously improved, are better than a nondeuterated compound lucitanib, and are indicated to have better safety and effectiveness, high bioavailability and good application prospect.
THERAPEUTIC COMPOUNDS AND USES THEREOF
-
, (2014/09/03)
Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.
Quinoline derivatives inhibiting the effect of growth factors such as VEGF
-
Page column 40, (2010/02/08)
Compounds of the formula (I): wherein: R2represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents —O—, —NH—, —S— or —CH2—; G1represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y1, Y2, Y3and Y4each independently represents carbon or nitrogen; R1represents fluoro or hydrogen; m is an integer from 1 to 3; R3represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR4R5(wherein R4and R5, can each be hydrogen or C1-3alkyl), or a group R6—X1— wherein X1represents —CH2— or a heteroatom linker group and R6is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or R6is an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals such as humans, processes for the preparation of such derivatives, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.